Efficacy, Safety, and Survival Factors for Sorafenib Treatment in Japanese Patients with Advanced Hepatocellular Carcinoma

Publisher： Karger

E-ISSN： 1423-0232|84|2|108-114

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.2, 2012-11, pp. : 108-114

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Germline BIM Deletion Polymorphism Is Not Associated with the Treatment Efficacy of Sorafenib in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 85, Iss. 5, 2013-11 ,pp. : 312-316

Karger

Access to resources Recommend Favorite

Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma

By  

Oncology, Vol. 91, Iss. 5, 2016-09 ,pp. : 261-266

Karger

Access to resources Recommend Favorite

Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib

By  

HEPATOLOGY, Vol. 62, Iss. 3, 2015-09 ,pp. : 784-791

John Wiley & Sons Inc

Access to resources Recommend Favorite

Sunitinib in Patients with Advanced Hepatocellular Carcinoma after Progression under Sorafenib Treatment

By  

Oncology, Vol. 79, Iss. 1-2, 2010-11 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 340-347

Karger

Access to resources Recommend Favorite